Distribution of adult patients with de novo EL treated by autologous or identical sibling allogeneic HSCT in first CR
| . | Autologous HSCT (103 patients) . | Identical sibling allogeneic HSCT (104 patients) . |
|---|---|---|
| Median age, y (range) | 40 (17-69) | 36 (16-63) |
| Male/female ratio | 57:46 | 54:50 |
| Median leukocyte count at diagnosis, × 109/L (range) | 3.8 (0.9-32) | 3 (0.8-200) |
| Median time from diagnosis to CR1, d (range) | 44 (24-199) | 47 (21-245) |
| Median time from CR1 to HSCT, d (range) | 120 (37-324) | 99 (10-351) |
| Conditioning regimen, % | ||
| With TBI | 26 | 56 |
| With busulfan | 38 | 31 |
| Other chemotherapy alone | 26 | 9 |
| Missing data | 10 | 5 |
| Source of stem cells, % | ||
| Bone marrow | 51 | 74 |
| Peripheral blood | 43 | 23 |
| Both | 6 | 3 |
| GVHD prophylaxis, % | ||
| Cyclosporin + methotrexate | — | 62 |
| T-cell depletion | — | 22 |
| Other | — | 17 |
| . | Autologous HSCT (103 patients) . | Identical sibling allogeneic HSCT (104 patients) . |
|---|---|---|
| Median age, y (range) | 40 (17-69) | 36 (16-63) |
| Male/female ratio | 57:46 | 54:50 |
| Median leukocyte count at diagnosis, × 109/L (range) | 3.8 (0.9-32) | 3 (0.8-200) |
| Median time from diagnosis to CR1, d (range) | 44 (24-199) | 47 (21-245) |
| Median time from CR1 to HSCT, d (range) | 120 (37-324) | 99 (10-351) |
| Conditioning regimen, % | ||
| With TBI | 26 | 56 |
| With busulfan | 38 | 31 |
| Other chemotherapy alone | 26 | 9 |
| Missing data | 10 | 5 |
| Source of stem cells, % | ||
| Bone marrow | 51 | 74 |
| Peripheral blood | 43 | 23 |
| Both | 6 | 3 |
| GVHD prophylaxis, % | ||
| Cyclosporin + methotrexate | — | 62 |
| T-cell depletion | — | 22 |
| Other | — | 17 |